BIOETHICS LTD financial data

Location
Ogden, UT
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 13 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.2% % 2556%
Debt-to-equity -101% % -1.2%
Return On Equity 20% % 56%
Return On Assets -1682% % 94%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,600,194 shares 217%
Common Stock, Shares, Outstanding 3,335,194 shares 194%
Entity Public Float $292,914 USD 971%
Common Stock, Value, Issued $3,335 USD 194%
Weighted Average Number of Shares Outstanding, Basic 1,493,117 shares 32%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
General and Administrative Expense $122,817 USD 143%
Operating Income (Loss) $122,817 USD -143%
Nonoperating Income (Expense) $49,988 USD -4.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $176,955 USD -82%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $176,955 USD -82%
Earnings Per Share, Basic 0 USD/shares -25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $14,664 USD 10526%
Assets, Current $14,664 USD 10526%
Assets $14,664 USD 10526%
Accounts Payable, Current $192,788 USD 58%
Accrued Liabilities, Current $108,887 USD 22%
Liabilities, Current $945,884 USD 22%
Liabilities $945,884 USD 22%
Retained Earnings (Accumulated Deficit) $1,454,834 USD -14%
Stockholders' Equity Attributable to Parent $931,220 USD -20%
Liabilities and Equity $14,664 USD 10526%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,895 USD -94%
Net Cash Provided by (Used in) Financing Activities $5,850 USD 95%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 3,335,194 shares 194%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14,664 USD 10526%
Deferred Tax Assets, Valuation Allowance $326,000 USD 13%
Deferred Tax Assets, Operating Loss Carryforwards $298,000 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Additional Paid in Capital $520,279 USD 4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $54,138 USD 16%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%